

Conexeu is building a new class of aesthetic and wound care products from patented ground breaking research.



Investment Rationale

INNOVATIVE COLLAGEN SCAFFOLD

Our clinically validated scaffold technology has been engineered to solve problems with existing market collagen and aesthetic products. We bring superior biologic advantages with a liquid skin substitute.

SOLID INTELLECTUAL PROPERTY

Conexeu has acquired the patents. Over \$4.5M & 10 years have been invested in the development of the IP, with diverse indications in aesthetics, wound care, and tissue engineering.

Patents granted: USA, JP, EU, AUS CAN (examination).



ACCELERATED MARKET ENTRY

1. Efficient Commercial Path: targeting 2 key markets, aesthetics and wound care.
2. Cost-Efficient Regulatory Benefits: 1 - 510(k) predicate device significantly reduces cost to entry.
3. Market Diversification: multiple indications provide lower-risk, high-reward opportunities.
4. Diverse Market Comps: IP valuations ranging from \$25 million to ~\$200 million per indication.
5. Substantially lower financial burden in comparison to standard biotech ventures.

ADVANTAGES OF THE CXU SCAFFOLD

- + **LIQUID SKIN SUBSTITUTE:** liquid forms into complete gel in the body, in about 10 minutes.
- + **CLINICALLY PROVEN** in pilot studies for wound repair (Flaps/ Mesh Skin Grafts).
- + **NON-TOXIC:** avoids key issues of toxins and allergic reactions with existing derm-fillers.
- + **NON-SURGICAL:** provides an alternative to implants and liposuction procedures. Meets growing market preference towards minimally invasive solutions.

Existing Market Challenges

1. **AESTHETIC MARKET - SMALL VOLUME:** dermal fillers have issues of toxicity, low durability, inflammation, and unsuitability for larger volume indications.
2. **AESTHETIC MARKET - LARGE VOLUME:** surgical issues in liposuction, large volume fat grafting or implants. These are invasive, pose risks, need extended recovery, and may have inconsistent outcomes.
3. **WOUND CARE:** commercial collagen's are already gelled when injected into a wound and are not smooth. These 'fibrillated collagen's do not fill wounds and then gel.

Market Opportunity

CXU Scaffold: one product, multiple indications

- + **AESTHETIC MARKET: \$8.25 billion in 2022*:** CXU has developed a safe, non-toxic, non-surgical product for the derm-filler, hand filler, and large volume body contouring market.
- + **WOUND CARE: \$22.5 Billion in 2022*:** superior biologic method of action as a liquid skin substitute for cellular regeneration for better outcomes and reduced recovery times. * <https://www.grandviewresearch.com/>

AWARDS

	Awarded Top Doctoral Thesis U.B.C		
	Vancouver Coastal Health Innovation and Translational Research Award		
	Vancouver General Hospital Bradshaw Award		
	MSFHR Innovation to Commercialization Awards 2017		
	Awarded a \$750,000 Grant by Canadian Institute of Health Research		
FUNDED BY:			

Management & Advisors



Jeff Sharpe

CEO, Director
+(604) 808 6211 4722

- + Drawing on a track record of entrepreneurial success, Jeff has spearheaded multiple ventures, including taking a Canadian biotech from startup to IPO, raising **\$30M in 9 months**.
- + He guided numerous private companies to public listings, generating over **\$100M** in combined private and public market financing, with deep expertise in IPOs and M&A.
- + Jeff remains focused on public-market biotech, guiding emerging companies to accelerate growth and achieve successful exits.



Dr. Brian K Pilcher PhD.

President, Chief Medical Officer

- + 25+ years in dermatology and aesthetics, served as **CMO of Suneva Medical** and **VP of Medical Affairs** for **Merz North America**, leading the launch of **Radiesse**.
- + Led medical affairs teams and 40+ educators to ensure optimal clinical outcomes, patient safety, and successful product life cycles in aesthetic medicine.
- + Spearheaded scientific and clinical initiatives to enhance regenerative aesthetic technologies, ensuring safe, effective treatments and advancing industry standards.



Dr. Claudia Chavez, M.D. Ph.D.

Chief Scientific Officer, Founder

- + M.D. Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City.
- + **Ph.D. (Experimental Medicine)** Department of Surgery, Div. Plastic and Reconstructive Surgery.
- + Developed, patented and sold an enclosed, implantable bioreactor to the U.S. Department of Defence (D.O.D).



CONEXEU

David Bogart, CCO, Founder Director

davidbogart@conexeu.com
+(604) 315 4722

- + Capital markets advisor for US and Canadian companies. Experience with IPO's and reverse mergers on major stock exchanges, \$60M+ public and private capital raised.



**Dr. Paul Lorenc,
MD, FACS**

Advisor

- + Dr. Lorenc is board certified by the **American Board of Plastic Surgery**, a fellow of the **American College of Surgeons**, and a member of the **International and American Societies of Plastic Surgeons**.
- + **2 - \$150M+ exits** in the aesthetics start up space, including an FDA approved porcine collagen filler.
- + Clinical and FDA studies for Allergan, Galderma, Suneva, J&J with over 140 peer-reviewed medical research papers.



**Dr. Vijay Gorantla
MD, PhD, FRCS**

Advisor

- + Dr. Gorantla is a tenured professor of surgery at Wake Forest University School of Medicine and Regenerative Medicine.
- + His research interests include cellular therapies, organ transplantations, regenerative medicine, and re-constructive surgeries.
- + Dr. Gorantla was a key member of the team that performed the first U.S hand transplant, sponsored by the U.S. Department of Defense.



**Dr. Scott Rineer
MD, MPH**

Advisor

- + Dr. Rineer is a Fellow of the American Academy of **Emergency Medicine** and a Fellow of the American College of Emergency Physicians. In addition, he is a member of the **American Medical Association** and the **Florida Medical Association**.
- + **U.S. Marine Corps Surgeon Forces Central** including **service in Afghanistan**.
- + U.S. Navy/USMC parachutist.
- + Expert in acute wounds and trauma injuries.



Michael Wright, Director

mw@conexeu.com

- + Over 25 years experience in the financial industry, he has served many commercial industry leaders, both private and publicly listed companies as well as traditional financial and institutional lenders.